took too much retatrutide VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide: The "Triple G" Peptide

Melanotan II in psychogenic erectile dysfunction

However, based on the populations studied in clinical trials to date, researchers have focused primarily on adults living with obesity typically defined as a body mass index (BMI) of 30 kg/m or above as well as those with overweight accompanied by at least one weight-related health condition, such as type 2 diabetes, hypertension, or dyslipidaemia

doi: 10.1186/s12974-019-1564-7 26 BrusciaE

Compared with people starting topiramate, those starting GLP-1 drugs were 48% less likely to start valproate, 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies, 35% less likely to start tricyclic antidepressants, and 23% less likely to start the class of drugs called gepants

The 68-week study showed participants on CagriSema lost about 23% of their body weight, compared with 12% for those taking cagrilintide by itself, 16% for those on semaglutide, and 2.3% for people on a placebo